Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-100LI in Patients With Vocal Fold Scar
NCT05627648Phase 3Active, not recruiting
- Sponsor
- Kringle Pharma, Inc.
- Start
- Dec 2022
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of KP-100 in vocal fold scar, sponsored by Kringle Pharma, Inc.. Started Dec 2022; status: active, not recruiting.
02
Drugs
KP-100
03
Conditions
vocal fold scar
Beyond the preview
Go deeper on NCT05627648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627648.